Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15

Huiyuan Zhu,Man Li,Dexi Bi,Huiqiong Yang,Yaohui Gao,Feifei Song,Jiayi Zheng,Ruting Xie,Youhua Zhang,Hu Liu,Xuebing Yan,Cheng Kong,Yefei Zhu,Qian Xu,Qing Wei,Huanlong Qin
DOI: https://doi.org/10.1038/s41467-024-45572-w
IF: 16.6
2024-02-25
Nature Communications
Abstract:Fusobacterium nucleatum ( F. nucleatum ) promotes intestinal tumor growth and its relative abundance varies greatly among patients with CRC, suggesting the presence of unknown, individual-specific effectors in F. nucleatum -dependent carcinogenesis. Here, we identify that F. nucleatum is enriched preferentially in KRAS p.G12D mutant CRC tumor tissues and contributes to colorectal tumorigenesis in Villin-Cre/Kras G12D+/- mice. Additionally, Parabacteroides distasonis ( P. distasonis ) competes with F. nucleatum in the G12D mouse model and human CRC tissues with the KRAS mutation. Orally gavaged P. distasonis in mice alleviates the F. nucleatum -dependent CRC progression. F. nucleatum invades intestinal epithelial cells and binds to DHX15, a protein of RNA helicase family expressed on CRC tumor cells, mechanistically involving ERK/STAT3 signaling. Knock out of Dhx15 in Villin-Cre/Kras G12D+/- mice attenuates the CRC phenotype. These findings reveal that the oncogenic effect of F. nucleatum depends on somatic genetics and gut microbial ecology and indicate that personalized modulation of the gut microbiota may provide a more targeted strategy for CRC treatment.
multidisciplinary sciences
What problem does this paper attempt to address?
This paper aims to explore how *Fusobacterium nucleatum* promotes the development of KRAS p.G12D mutant colorectal cancer (CRC) and to reveal the underlying mechanisms. Specifically, the researchers found: 1. **Enrichment of *Fusobacterium nucleatum* in KRAS p.G12D mutant CRC tissues**: Through quantitative polymerase chain reaction (qPCR) and exome sequencing analysis, the researchers found that the abundance of *Fusobacterium nucleatum* in KRAS p.G12D mutant CRC tumor tissues was significantly higher than in wild-type (WT) tissues and other mutation types (such as APC, TP53, MSH2, and SMAD4) tissues. 2. ***Fusobacterium nucleatum* exacerbates colorectal tumorigenesis in Villin-Cre/KrasG12D+/− mice**: By constructing a Villin-Cre/KrasG12D+/− mouse model, the researchers found that *Fusobacterium nucleatum* was enriched in the colon of these mice and exacerbated tumor occurrence and development. Compared with wild-type mice, *Fusobacterium nucleatum*-treated Villin-Cre/KrasG12D+/− mice exhibited more tumors and a greater tumor burden. 3. ***Parabacteroides distasonis* competes with *Fusobacterium nucleatum***: The study found that in the Villin-Cre/KrasG12D+/− mouse model and human KRAS mutant CRC tissues, *Parabacteroides distasonis* competes with *Fusobacterium nucleatum*. Oral administration of *Parabacteroides distasonis* can alleviate *Fusobacterium nucleatum*-dependent CRC progression. 4. ***Fusobacterium nucleatum* invades tumor cells and binds to DHX15**: The researchers found that *Fusobacterium nucleatum* can invade KRAS p.G12D mutant tumor cells and bind to the RNA helicase family member DHX15. This binding involves the activation of the ERK/STAT3 signaling pathway, leading to the upregulation of DHX15 expression. 5. **Knockout of DHX15 weakens the CRC phenotype**: After knocking out the Dhx15 gene in Villin-Cre/KrasG12D+/− mice, the CRC phenotype was significantly weakened, indicating the critical role of DHX15 in *Fusobacterium nucleatum*-promoted CRC development. In summary, this paper reveals the mechanism by which *Fusobacterium nucleatum* promotes the development of KRAS p.G12D mutant CRC through binding to DHX15 and activating the ERK/STAT3 signaling pathway, and proposes potential strategies for personalized treatment by modulating the gut microbiota.